Status:
COMPLETED
Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the tolerability and safety profile of BMS-833923 (XL139) when orally administered on a once daily schedule.
Eligibility Criteria
Inclusion
- Subjects with advanced or metastatic solid tumors refractory to, or relapsed from, standard therapies or for which there is no known effective treatment
- Men and woman, 20 years of age and above
Exclusion
- Subjects with symptomatic brain metastasis or active brain metastasis requiring treatments
- Inability to swallow oral medication
- Uncontrolled or significant cardiovascular disease
- Inadequate bone marrow function
- Inadequate hepatic function
- Inadequate renal function
- Pancreatitis
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01413906
Start Date
November 1 2011
End Date
November 1 2012
Last Update
June 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Kashiwa-shi, Chiba, Japan, 2778577